1
|
Szafrański PW, Siwek A, Smaga-Maślanka I, Pomierny-Chamioło L, Ilnicki P, Żuchowski G, Nevalainen T, Filip M, Zajdel P, Cegła MT. Synthesis, relative configuration and CB1 receptor affinity studies for a set of 1,2,3-triazole derivatives. J Mol Struct 2023. [DOI: 10.1016/j.molstruc.2023.135223] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/25/2023]
|
2
|
Chen L, Yan G, Ohwada T. Building on endogenous lipid mediators to design synthetic receptor ligands. Eur J Med Chem 2022; 231:114154. [DOI: 10.1016/j.ejmech.2022.114154] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2021] [Revised: 01/17/2022] [Accepted: 01/22/2022] [Indexed: 01/05/2023]
|
3
|
Synthesis and structural studies of 3,6-disubstituted-bis-1,2,4-triazolo-[4,3-b][3′,4′-f]pyridazines. J Mol Struct 2019. [DOI: 10.1016/j.molstruc.2019.02.082] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
4
|
Horký P, Voráčová M, Konečná K, Sedlák D, Bartůněk P, Vacek J, Kuneš J, Pour M. Nontoxic combretafuranone analogues with high in vitro antibacterial activity. Eur J Med Chem 2018; 143:843-853. [PMID: 29223099 DOI: 10.1016/j.ejmech.2017.11.078] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2017] [Revised: 11/27/2017] [Accepted: 11/27/2017] [Indexed: 12/12/2022]
Abstract
A library of thirty two 3,4-diphenylfuranones related to both combretastatin A-4 and antifungal 5-(acyloxymethyl)-3-(halophenyl)-2,5-dihydrofuran-2-ones was prepared. Cytotoxic effects on a panel of cancer and normal cell lines and antiinfective activity were evaluated, and the data were complemented with tests for the activation of caspase 3 and 7. High cytotoxicity was observed in some of the halogenated analogues, eg. 3-(3,4-dichlorophenyl)-4-(4-methylphenyl)-2,5-dihydrofuran-2-one with IC50 0.12-0.23 μM, but the compounds were also highly toxic against non-malignant control cells. More importantly, notable antibacterial activity indicating G+ selectivity has been found in the 3,4-diarylfuranone class of compounds for the first time. Hydroxymethylation of furanone C5 knocked out cytotoxic effects (up to 40 μM) while maintaining significant activity against Staphylococcus strains in some derivatives. MIC95 of the most promising compound, 3-(4-bromophenyl)-5,5-bis(hydroxymethyl)-4-(4-methylphenyl)-2,5-dihydrofuran-2-one against S. aureus strain ATCC 6538 was 0.98 μM (0.38 μg/mL) and 3.9 μM (1.52 μg/mL) after 24 and 48 h, respectively.
Collapse
Affiliation(s)
- P Horký
- Department of Bioorganic and Organic Chemistry, Faculty of Pharmacy, Charles University, Heyrovského 1203, 500 05 Hradec Králové, Czech Republic
| | - M Voráčová
- Department of Bioorganic and Organic Chemistry, Faculty of Pharmacy, Charles University, Heyrovského 1203, 500 05 Hradec Králové, Czech Republic
| | - K Konečná
- Department of Biological and Medical Sciences, Faculty of Pharmacy, Charles University, Heyrovského 1203, 500 05 Hradec Králové, Czech Republic
| | - D Sedlák
- CZ-OPENSCREEN: National Infrastructure for Chemical Biology, Institute of Molecular Genetics, Czech Academy of Sciences, Vídeňská 1083, 142 20 Praha 4, Czech Republic
| | - P Bartůněk
- CZ-OPENSCREEN: National Infrastructure for Chemical Biology, Institute of Molecular Genetics, Czech Academy of Sciences, Vídeňská 1083, 142 20 Praha 4, Czech Republic
| | - J Vacek
- Department of Medical Chemistry and Biochemistry, Palacký University, Hněvotínská 3, 775 15 Olomouc, Czech Republic
| | - J Kuneš
- Department of Bioorganic and Organic Chemistry, Faculty of Pharmacy, Charles University, Heyrovského 1203, 500 05 Hradec Králové, Czech Republic
| | - M Pour
- Department of Bioorganic and Organic Chemistry, Faculty of Pharmacy, Charles University, Heyrovského 1203, 500 05 Hradec Králové, Czech Republic.
| |
Collapse
|
5
|
Developing pyridazine-3-carboxamides to be CB2 agonists: The design, synthesis, structure-activity relationships and docking studies. Eur J Med Chem 2017. [DOI: 10.1016/j.ejmech.2017.05.060] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
6
|
Qian HY, Wang ZL, Pan YL, Chen LL, Xie X, Chen JZ. Development of Quinazoline/Pyrimidine-2,4(1 H,3 H)-diones as Agonists of Cannabinoid Receptor Type 2. ACS Med Chem Lett 2017. [PMID: 28626532 DOI: 10.1021/acsmedchemlett.7b00007] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Starting from a prototypical structure 1, we describe our efforts to design and obtain novel quinazoline/pyrimidine-2,4(1H,3H)-diones with high CB2 agonist potency and selectivity as well as improved physicochemical characteristics, mainly hydrophilicity. The most potent and selective CB2 agonists, 8 and 36, in this series were also endowed with lower logP values than that of GW842166X and lead compound 1. These derivatives appear to be promising lead compounds for the development of future CB2 agonists.
Collapse
Affiliation(s)
- Hai-Yan Qian
- College
of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang 310058, P. R. China
| | - Zhi-Long Wang
- CAS
Key Laboratory of Receptor Research, National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, P. R. China
| | - You-Lu Pan
- College
of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang 310058, P. R. China
| | - Li-Li Chen
- College
of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang 310058, P. R. China
| | - Xin Xie
- CAS
Key Laboratory of Receptor Research, National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, P. R. China
| | - Jian-Zhong Chen
- College
of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang 310058, P. R. China
| |
Collapse
|
7
|
Tran SB, Maxwell BD, Burrell R, Bonacorsi SJ. The syntheses of isotopically labelled CB-1 antagonists for the treatment of obesity. J Labelled Comp Radiopharm 2016; 59:665-672. [PMID: 27624665 DOI: 10.1002/jlcr.3433] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2016] [Revised: 07/07/2016] [Accepted: 07/22/2016] [Indexed: 11/06/2022]
Abstract
BMS-725519, BMS-811064, and BMS-812204 are potent and selective central cannabinoid receptor antagonists that have been investigated for the treatment of human obesity. To further understand their biotransformation profiles, radiolabelled and stable-labelled products were required. This paper describes the utility of [14 C]1,1-carbonyldiimidazole as a radiolabelling reagent for the syntheses of carbonyl-labelled [14 C]BMS-725519, [14 C]BMS-811064, and [14 C]BMS-812204. The syntheses of stable-labelled [13 C6 ]BMS-725519 and [13 CD313 CD2 ]BMS-812204 synthesized from of [13 C6 ]4-chloroacetophenone and [13 CD313 CD2 ]iodoethane, respectively, are also described.
Collapse
Affiliation(s)
- Scott B Tran
- Discovery Chemistry Platforms - Radiochemistry, Bristol-Myers Squibb, Inc, P.O. Box 4000, Princeton, NJ, 08543, USA
| | - Brad D Maxwell
- Discovery Chemistry Platforms - Radiochemistry, Bristol-Myers Squibb, Inc, P.O. Box 4000, Princeton, NJ, 08543, USA
| | - Richard Burrell
- Discovery Chemistry Platforms - Radiochemistry, Bristol-Myers Squibb, Inc, P.O. Box 5100, Wallingford, CT, 06492, USA
| | - Samuel J Bonacorsi
- Discovery Chemistry Platforms - Radiochemistry, Bristol-Myers Squibb, Inc, P.O. Box 4000, Princeton, NJ, 08543, USA
| |
Collapse
|
8
|
Mugnaini C, Brizzi A, Ligresti A, Allarà M, Lamponi S, Vacondio F, Silva C, Mor M, Di Marzo V, Corelli F. Investigations on the 4-Quinolone-3-carboxylic Acid Motif. 7. Synthesis and Pharmacological Evaluation of 4-Quinolone-3-carboxamides and 4-Hydroxy-2-quinolone-3-carboxamides as High Affinity Cannabinoid Receptor 2 (CB2R) Ligands with Improved Aqueous Solubility. J Med Chem 2016; 59:1052-67. [DOI: 10.1021/acs.jmedchem.5b01559] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Affiliation(s)
- Claudia Mugnaini
- Dipartimento
di Biotecnologie, Chimica e Farmacia, Università degli Studi di Siena, Via Aldo Moro 2, 53100 Siena, Italy
| | - Antonella Brizzi
- Dipartimento
di Biotecnologie, Chimica e Farmacia, Università degli Studi di Siena, Via Aldo Moro 2, 53100 Siena, Italy
| | - Alessia Ligresti
- Endocannabinoid
Research Group, Istituto di Chimica Biomolecolare, Consiglio Nazionale delle Ricerche, Via dei Campi Flegrei 34, 80078 Pozzuoli (Napoli), Italy
| | - Marco Allarà
- Endocannabinoid
Research Group, Istituto di Chimica Biomolecolare, Consiglio Nazionale delle Ricerche, Via dei Campi Flegrei 34, 80078 Pozzuoli (Napoli), Italy
| | - Stefania Lamponi
- Dipartimento
di Biotecnologie, Chimica e Farmacia, Università degli Studi di Siena, Via Aldo Moro 2, 53100 Siena, Italy
| | - Federica Vacondio
- Dipartimento
di Farmacia, Università degli Studi di Parma, Parco Area
delle Scienze 27/A, 43124 Parma, Italy
| | - Claudia Silva
- Dipartimento
di Farmacia, Università degli Studi di Parma, Parco Area
delle Scienze 27/A, 43124 Parma, Italy
| | - Marco Mor
- Dipartimento
di Farmacia, Università degli Studi di Parma, Parco Area
delle Scienze 27/A, 43124 Parma, Italy
| | - Vincenzo Di Marzo
- Endocannabinoid
Research Group, Istituto di Chimica Biomolecolare, Consiglio Nazionale delle Ricerche, Via dei Campi Flegrei 34, 80078 Pozzuoli (Napoli), Italy
| | - Federico Corelli
- Dipartimento
di Biotecnologie, Chimica e Farmacia, Università degli Studi di Siena, Via Aldo Moro 2, 53100 Siena, Italy
| |
Collapse
|
9
|
Perola E, Stamos D, Grillot AL, Ronkin S, Wang T, LeTiran A, Tang Q, Deininger DD, Liao Y, Tian SK, Drumm JE, Nicolau DP, Tessier PR, Mani N, Grossman TH, Charifson PS. Successful application of serum shift prediction models to the design of dual targeting inhibitors of bacterial gyrase B and topoisomerase IV with improved in vivo efficacy. Bioorg Med Chem Lett 2014; 24:2177-81. [PMID: 24685546 DOI: 10.1016/j.bmcl.2014.03.022] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2014] [Accepted: 03/07/2014] [Indexed: 11/28/2022]
Abstract
A series of dual targeting inhibitors of bacterial gyrase B and topoisomerase IV were identified and optimized to mid-to-low nanomolar potency against a variety of bacteria. However, in spite of seemingly adequate exposure achieved upon IV administration, the in vivo efficacy of the early lead compounds was limited by high levels of binding to serum proteins. To overcome this limitation, targeted serum shift prediction models were generated for each subclass of interest and were applied to the design of prospective analogs. As a result, numerous compounds with comparable antibacterial potency and reduced protein binding were generated. These efforts culminated in the synthesis of compound 10, a potent inhibitor with low serum shift that demonstrated greatly improved in vivo efficacy in two distinct rat infection models.
Collapse
Affiliation(s)
- Emanuele Perola
- Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, MA 02210, United States.
| | - Dean Stamos
- Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, MA 02210, United States
| | - Anne-Laure Grillot
- Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, MA 02210, United States
| | - Steven Ronkin
- Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, MA 02210, United States
| | - Tiansheng Wang
- Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, MA 02210, United States
| | - Arnaud LeTiran
- Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, MA 02210, United States
| | - Qing Tang
- Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, MA 02210, United States
| | - David D Deininger
- Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, MA 02210, United States
| | - Yusheng Liao
- Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, MA 02210, United States
| | - Shi-Kai Tian
- Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, MA 02210, United States
| | - Joseph E Drumm
- Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, MA 02210, United States
| | - David P Nicolau
- Center for Anti-Infective Research and Development, Hartford Hospital, 80 Seymour Street, Hartford, CT 06102, United States
| | - Pamela R Tessier
- Center for Anti-Infective Research and Development, Hartford Hospital, 80 Seymour Street, Hartford, CT 06102, United States
| | - Nagraj Mani
- Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, MA 02210, United States
| | - Trudy H Grossman
- Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, MA 02210, United States
| | - Paul S Charifson
- Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, MA 02210, United States
| |
Collapse
|